Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Isotechnika Pharma Inc IPHAF

GREY:IPHAF - Post Discussion

Isotechnika Pharma Inc > gee, what happened to uveitis
View:
Post by antoninus on Jan 19, 2012 11:15am

gee, what happened to uveitis

hmmmm....no word on the reschedule of the FDA gaffe?

 

psoriasis will never repay what it took to advance the trials only to drop it...

 

and no, the stock wont rise pre phase 3 or pre commericalization IF they get that far...why not? because NO ONE gives a rats butt about this stock...no one even really knows about them...and those that do, have been burned too many times and dont trust that mngmt knows what their doing.
 

the stock will drift downward over the next 2-3 yrs.

Comment by narcissist on Jan 25, 2012 3:56am
There is not much news available on uveitus other than the fact that the application remains viable. LUX is still recruiting patients for a stage 3 clinical trial (study identifier NCT01243983). The ClinicalTrial.gov web site - a service of the US National Institutes of Health - indicates that the LUX study is designed to study the "Efficacy and Safety of Voclosporin to Treat Active ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities